Kiora Pharmaceuticals, Inc.
KPRXKiora Pharmaceuticals, Inc. in brief
Kiora Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Encinitas, California, USA. Its market value was $8 M on 30 October 2026, which makes it the 26,348th largest listed company in the world and the 4,342nd largest in the USA on this site. Brian M. Strem is its chief executive. Its largest business segments by sales in 2024 were Reportable (100%). Its shares trade under the symbol KPRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Kiora Pharmaceuticals, Inc.
We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa. KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP. We completed a Phase 1b clinical trial in September 2023 and presented topline results in November 2023 at the American Academy of Ophthalmology Annual Meeting. The full data package triggered multiple discussions with various potential pharmaceutical partners. After assessing available options, in January 2024, we partnered with Théa Open Innovation, a sister company of Laboratories Théa. In October 2024, we received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 in patients with retinitis pigmentosa. The ABACUS-2 trial is a 36 patient, multicenter, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa. Enrollment in the ABACUS-2 trial is currently ongoing. As KIO-301 and its sister molecules are ion channel modulators, the potential to treat other neurological diseases exists. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. transaction which closed October 21, 2021.
From the company's annual report filed with the US SEC: read the report
Kiora Pharmaceuticals, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- ✎Renamed Kiora Pharmaceuticals IncFormerly Eyegate Pharmaceuticals Inc.
- 2024
- 💰Record revenue of $16 millionFY2024, the highest of the 4 years on record.
Events of Kiora Pharmaceuticals, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,847 (Dec 2022) · #5,654 (Jul 2023) · #4,656 (Jan 2024) · #2,417 (Mar 2026) · #4,033 (Aug 2026) · #4,345 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.5×
- Free cash flow yield
- -129.3%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -67.2%
- Liabilities / assets
- 33.5%
- Net debt
- $-1M
- Revenue growth
- +160100.0%
- R&D / revenue
- 48.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-13M | $-11M | — |
| Dec 2024 | $16M | — | $5M | $4M | 22.4% |
| Dec 2023 | — | — | $-13M | $-13M | — |
| Dec 2022 | — | — | $-12M | $-14M | — |
| Dec 2021 | — | — | $-14M | $-14M | — |
| Dec 2020 | $0M | -99.6% | $-7M | $-7M | -68600.0% |
| Dec 2019 | $3M | +63.0% | — | $-7M | -263.9% |
| Dec 2018 | $2M | — | $-11M | $-11M | -655.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-10M | $0M | $-10M | $-2.64 | — |
| Dec 2024 | $9M | $0M | $9M | $0.87 | — |
| Dec 2023 | $-10M | $0M | $-10M | $-24.25 | — |
| Dec 2022 | $-10M | $0M | $-10M | $-18.55 | — |
| Dec 2021 | $-11M | $0M | $-11M | $-57.12 | — |
| Dec 2020 | $-7M | $0M | $-7M | $-1.49 | — |
| Dec 2019 | $-8M | $0M | $-8M | $-2.23 | — |
| Dec 2018 | $-11M | $0M | $-11M | $-4.57 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 29, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Sep 8, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 19, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Aug 7, 20268-KCurrent reportResults of operations
- Aug 7, 202610-QQuarterly report · period to Jun 2026
- Jun 18, 20268-KCurrent reportRegulation FD disclosure
- Jun 11, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 8, 20268-KCurrent reportResults of operations
- May 8, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 2026DEF 14AProxy statement
Official filings of Kiora Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-13 M
- Net income
- $-11 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $24 M
- Total liabilities
- $8 M
- Total equity
- $16 M
As of December-2025
Top 21 institutional investors in Kiora Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Perceptive Advisors LLC | 438,471 | 0 (0.00%) | 9.91% | $1 M | Nov 16, 2026 |
| 2 | Millennium Management LLC | 176,784 | +102,582 (+138.25%) | 4.00% | $0 M | Nov 16, 2026 |
| 3 | ADAR1 Capital Management, LLC | 167,941 | 0 (0.00%) | 3.80% | $0 M | Nov 16, 2026 |
| 4 | Citadel Advisors LLC | 86,739 | -29,272 (-25.23%) | 1.96% | $0 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 46,083 | +19,366 (+72.49%) | 1.04% | $0 M | Nov 6, 2026 |
| 6 | Two Sigma Investments, LP | 39,944 | -48,848 (-55.01%) | 0.90% | $0 M | Nov 16, 2026 |
| 7 | Renaissance Technologies LLC | 37,200 | +7,376 (+24.73%) | 0.84% | $0 M | Nov 12, 2026 |
| 8 | Vanguard Capital Management LLC | 21,974 | +2,113 (+10.64%) | 0.50% | $0 M | Nov 13, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 17,730 | +4,700 (+36.07%) | 0.40% | $0 M | Nov 13, 2026 |
| 10 | HRT Financial LP | 16,873 | -41,739 (-71.21%) | 0.38% | $0 M | Nov 13, 2026 |
| 11 | XTX Topco Ltd | 16,396 | New | 0.37% | $0 M | Nov 16, 2026 |
| 12 | Dimensional Fund Advisors LP | 16,055 | +3,917 (+32.27%) | 0.36% | $0 M | Nov 4, 2026 |
| 13 | LPL Financial LLC | 12,500 | 0 (0.00%) | 0.28% | $0 M | Nov 6, 2026 |
| 14 | Northern Trust Corp | 11,767 | 0 (0.00%) | 0.27% | $0 M | Nov 16, 2026 |
| 15 | Caitong International Asset Management Co., Ltd | 1,624 | -189 (-10.42%) | 0.04% | $0 M | Oct 29, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 774 | -63 (-7.53%) | 0.02% | $0 M | Nov 16, 2026 |
| 17 | SBI Securities Co., Ltd. | 256 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 18 | Pinnacle Financial Group, Inc. | 250 | — | 0.01% | $0 M | Nov 16, 2026 |
| 19 | BlackRock, Inc. | 58 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 20 | Activest Wealth Management | 2 | 0 (0.00%) | 0.00% | $0 M | Oct 15, 2026 |
| 21 | Citigroup Inc | 1 | New | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Kiora Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 35,972 | $0 M | 0.81% | <0.01% | +75% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 19,861 | $0 M | 0.45% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 3,923 | $0 M | 0.09% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 3,446 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 3,510 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC | 2,000 | $0 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 1,895 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 1,574 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 1,236 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 747 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Kiora Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Melissa ToscaCFO | Shares withheld for tax | -911 | $2.660 | $2 K | 26,064 | Form 4 |
| filed | Brian M. StremPresident and CEO, Director | Shares withheld for tax | -1,869 | $2.660 | $5 K | 58,823 | Form 4 |
| filed | Eric Joseph DanielsChief Development Officer | Shares withheld for tax | -929 | $1.950 | $2 K | 31,741 | Form 4 |
| filed | Brian M. StremPresident and CEO, Director | Shares withheld for tax | -1,906 | $1.950 | $4 K | 60,692 | Form 4 |
| filed | Melissa ToscaCFO | Shares withheld for tax | -929 | $1.950 | $2 K | 26,975 | Form 4 |
| filed | Eric Joseph DanielsChief Development Officer | Grant or award | +6,533 | — | — | 32,670 | Form 4 |
| filed | Melissa ToscaCFO | Grant or award | +6,533 | — | — | 27,904 | Form 4 |
| filed | Brian M. StremPresident and CEO, Director | Grant or award | +16,733 | — | — | 62,598 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Kiora Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-9 reverse split ; 1-for-40 reverse split ; 1-for-16.67 reverse split
Trading halts
- 2025-06-04 14:09 UTC, code LUDP, resumed 14:14 UTC
Fails to deliver
- : 461 shares at $1.76
- : 5 shares at $2.69
- : 58,308 shares at $2.16
- : 2,222 shares at $2.07
- : 546 shares at $2.10
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Kiora Pharmaceuticals, Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-129.3%Free cash flow is -129.3% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.64 vs 0.87Diluted EPS -2.64 in fiscal 2025 against 0.87 the year before (report's currency).
- ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$7 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-51.8%-51.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.0×Current ratio 5.99 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year-0.5%Diluted shares down 0.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Kiora Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0−100%— | 16—100% | 0—— | — | 0−100%— | 0.0−99.6%100% | 2.7+62.5%100% | 1.7+306%100% | 0.4−39.1%100% | 0.7—100% | |
| Research and development | 11+37.5%— | 7.8+94.7%49.0% | 4.0+16.8%— | 3.4−35.5%— | 5.4+50.0%— | 3.6−33.8%29572% | 5.4−33.1%201% | 8.1−22.0%487% | 10+22.7%2535% | 8.4—1258% | |
| General and administrative | 5.7+3.7%— | 5.5+18.9%34.6% | 4.7−43.7%— | 8.3+55.5%— | 5.3+14.3%— | 4.7+5.7%38633% | 4.4−0.8%164% | 4.4−4.2%269% | 4.6−17.1%1138% | 5.6—836% | |
| Operating expenses | 13+11.5%— | 12−8.6%71.8% | 13+2.3%— | 12−13.5%— | 14r17+107%— | 6.9r8.2−29.8%57061% | 9.8−21.6%365% | 12−16.5%756% | 15+6.8%3673% | 14—2094% | |
| Operating income | −13−384%— | 4.5—28.2% | −13—— | −12—— | −14r−17—— | −6.9r−8.2—−56961% | — | −11—−656% | — | — | |
| Interest and finance income | 0.9−28.6%— | 1.3+620%7.8% | 0.2+206%— | 0.1+4886%— | 0.0−95.1%— | 0.0−78.4%194% | 0.1−10.2%4.0% | 0.1+21241%7.3% | 0.0−84.7%0.1% | 0.0—0.6% | |
| Interest expense and finance costs | 0.0−6.9%— | 0.0+92.7%0.1% | 0.0+29.5%— | 0.0+25.5%— | 0.0+63.7%— | 0.0+1188%34.7% | 0.0−68.8%0.0% | 0.0−14.4%0.1% | 0.0+342%0.3% | 0.0—0.0% | |
| Other non-operating income (expense) | 0.7−37.9%— | 1.1+604%7.2% | 0.2—— | −1.4−609%— | 0.3r0.2+1323%— | 0.0r0.1−82.2%159% | 0.1−9.7%4.0% | 0.1—7.2% | −0.0−119%−0.2% | 0.0—0.5% | |
| Income before tax | −12−314%— | 5.7—35.3% | −12—— | −14—— | −14r−17—— | −6.8r−8.1—−56802% | −7.0—−261% | −11—−649% | −15—−3573% | −13—−1994% | |
| Income tax | −1.3−162%— | 2.1+2186%12.9% | 0.1—— | −0.1—— | −0.2r−0.3−1698%— | 0.0−87.4%100.0% | 0.1+10.9%3.6% | 0.1—5.2% | −1.3—−329% | 0—0.0% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | −13—−3244% | −13—−1994% | |
| Minority interests' share of net income | — | — | — | — | — | — | — | — | −0.0—−0.0% | −0.0r0—−0.0% | |
| Net income attributable to shareholders | −11−401%— | 3.6—22.4% | −13—— | −14—— | −14r−16—— | −6.9r−8.1—−56902% | −7.1—−264% | −11—−654% | −13—−3244% | — | |
| Earnings per share, basic | -2.60−380%— | 0.93—— | -24.25r-2.69—— | -18.55—— | -57.12r-1.77—— | -1.49r-1.77—— | -2.23—— | -4.57r-0.30—— | -0.93—— | -1.51—— | |
| Earnings per share, diluted | -2.64−403%— | 0.87—— | -24.25r-2.69—— | -18.55—— | -57.12r-1.77—— | -1.49r-1.77—— | -2.23—— | -4.57r-0.30—— | -0.93—— | -1.51—— | |
| Shares, weighted average (basic) | 4.2+7.6%— | 3.9+620%— | 0.5r4.8−26.5%— | 0.7+204%— | 0.2r9.2−94.7%— | 4.6r4.6—— | — | — | — | — | |
| Shares, weighted average (diluted) | 4.1−0.5%— | 4.1+667%— | 0.5r4.8−26.5%— | 0.7+204%— | 0.2r9.2−94.7%— | 4.6r4.6+44.3%— | 3.2+34.5%— | 2.4r35−83.4%— | 14+61.4%— | 8.8—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 8.7+129%35.9% | 3.8+54.5%10.4% | 2.5−58.8%17.9% | 6.0−24.1%31.9% | 7.9+562%39.0% | 1.2−68.6%7.7% | 3.8−52.8%37.3% | 8.0+2.5%56.0% | 7.8+115%54.6% | 3.6—37.4% | |
| Short-term investments | 8.4−63.5%34.6% | 23—63.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Receivables | 1.5+153%6.3% | 0.6—1.6% | 0—0.0% | — | — | — | — | — | — | — | |
| Other current assets | 1.1−44.1%4.7% | 2.0+775%5.6% | 0.2−32.0%1.7% | 0.3−43.4%1.8% | 0.6+34.9%3.0% | 0.4−2.0%2.9% | 0.5+0.7%4.5% | 0.5−27.6%3.2% | 0.6+35.4%4.4% | 0.5—4.8% | |
| Current assets | 22−26.8%89.7% | 30+527%81.4% | 4.7−38.3%34.6% | 7.7−14.6%41.1% | 9.0+421%44.7% | 1.7r1.8−60.1%11.3% | 4.3−49.0%42.8% | 8.5+0.2%59.4% | 8.5+104%59.1% | 4.2—42.7% | |
| Property, plant and equipment | 0.1+1652%0.4% | 0.0−35.1%0.0% | 0.0−85.4%0.1% | 0.1−25.4%0.3% | 0.1+142%0.4% | 0.0+81.4%0.2% | 0.0−61.3%0.2% | 0.0−21.9%0.3% | 0.1+46.6%0.4% | 0.0—0.4% | |
| Right-of-use (leased) assets | 0.3+400%1.2% | 0.1−46.5%0.2% | 0.1−8.6%0.8% | 0.1−44.1%0.6% | 0.2+150%1.0% | 0.1—0.5% | — | 0—0.0% | — | — | |
| Goodwill | — | — | — | 0—0.0% | 0−100%0.0% | 3.6r3.5+138%23.7% | 1.50.0%15.1% | 1.50.0%10.7% | 1.5—10.7% | — | |
| Other intangible assets | 2.1−69.1%8.5% | 6.7−24.1%18.3% | 8.8−18.0%64.3% | 11−0.2%57.5% | 11r8.7+10.7%53.5% | 9.7+136%63.6% | 4.1−0.6%40.9% | 4.2+6.2%29.1% | 3.9—27.3% | — | |
| Total assets | 24−33.5%100% | 36+166%100% | 14−26.6%100% | 19−7.2%100% | 20r18+31.5%100% | 15r15+51.3%100% | 10−29.2%100% | 14−0.2%100% | 14+47.0%100% | 9.7—100% | |
| Accounts payable | 1.1+155%4.4% | 0.4+101%1.1% | 0.2−79.5%1.5% | 1.0+528%5.4% | 0.2−63.1%0.8% | 0.4+107%2.8% | 0.2+230%2.1% | 0.1−91.0%0.4% | 0.7−50.0%4.9% | 1.4—14.5% | |
| Current liabilities | 3.6−39.6%15.0% | 6.0+268%16.5% | 1.6−50.1%11.9% | 3.3+103%17.5% | 1.6−18.9%8.0% | 2.0r1.8+40.3%13.0% | 1.4−63.4%14.0% | 3.9−73.9%27.1% | 15+103%104% | 7.3—75.1% | |
| Long-term debt | — | — | — | — | — | 0.3—1.8% | 0—0.0% | — | — | — | |
| Lease liabilities (non-current) | 0.2+503%0.8% | 0.0−43.5%0.1% | 0.1—0.4% | 0−100%0.0% | 0.1+154%0.4% | 0.0—0.2% | 0—0.0% | — | — | — | |
| Non-current liabilities | 4.5−4.7%18.5% | 4.7−21.0%12.9% | 6.0+49.3%43.5% | 4.0+1.4%21.4% | 3.9r7.2+9.8%19.6% | 3.6r6.4+73.0%23.5% | 2.1+40.2%20.5% | 1.5+5.8%10.4% | 1.4−49.2%9.8% | 2.8—28.3% | |
| Total liabilities | 8.1−24.2%33.5% | 11+41.1%29.4% | 7.6+4.6%55.4% | 7.3+31.0%38.9% | 5.6r8.8−0.4%27.6% | 5.6r8.2+59.7%36.4% | 3.5−34.7%34.5% | 5.3−67.1%37.4% | 16+61.4%113% | 10—103% | |
| Retained earnings | −154—−636% | −143—−393% | −147—−1072% | −134—−720% | −121r−125—−600% | −107r−108—−700% | −100—−991% | −93—−652% | −92—−642% | −79—−808% | |
| Shareholders' equity | 16−37.4%66.5% | 26+322%70.6% | 6.1−46.4%44.6% | 11−21.8%61.1% | 15r9.2+49.8%72.4% | 9.7r7.0+46.9%63.6% | 6.6−25.9%65.5% | 8.9—62.6% | −1.9r−1.9—−13.5% | −0.3—−3.4% | |
| Total equity | — | — | — | — | — | — | — | 8.9+18.3%62.6% | 7.6r−1.9—52.8% | −0.3—−3.4% | |
| Total liabilities and equity | 24−33.5%100% | 36+166%100% | 14−26.6%100% | 19−7.2%100% | 20r18+31.5%100% | 15r15+51.3%100% | 10−29.2%100% | 14−0.2%100% | 14+47.0%100% | 9.7—100% | |
| Shares outstanding | 3.8+25.4%— | 3.0+250%— | 0.9r7.7−52.3%— | 1.8+467%— | 0.3r13−94.3%— | 5.6+36.3%— | 4.1+34.2%— | 3.0r44−82.4%— | 17+70.3%— | 10—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0+29.1%— | 0.0−62.9%0.1% | 0.1+24.5%— | 0.0−8.1%— | 0.0+35.6%— | 0.0−35.4%277% | 0.1+34.3%1.9% | 0.0+99.5%2.3% | 0.0+272%4.7% | 0.0—0.8% | |
| Share-based compensation | 0.9+37.1%— | 0.7−13.0%4.1% | 0.8+63.2%— | 0.5−45.1%— | 0.8+16.4%— | 0.7−15.1%6003% | 0.9−2.6%31.7% | 0.9+0.6%53.0% | 0.9+70.3%214% | 0.5—76.4% | |
| Cash from operating activities | −10.0−216%— | 8.6—53.4% | −9.6—— | −10—— | −11r−11—— | −7.3—−60678% | −8.2—−304% | −11—−656% | −6.5—−1587% | −8.4—−1257% | |
| Capital expenditure | −0.1—— | −0.0—−0.0% | 0—— | 0—— | −0.1—— | −0.0—−166% | 0—0.0% | −0.0—−1.2% | −0.0—−9.1% | 0—0.0% | |
| Intangible assets bought | — | — | — | — | — | — | — | −0.3—−15.1% | 0—0.0% | — | |
| Acquisitions, net of cash acquired | — | — | — | 0—— | −0.1—— | −0.1—−918% | — | — | — | — | |
| Cash from investing activities | 14—— | −23—−141% | 0−100%— | 0.0—— | −0.2—— | −0.2—−2027% | 0—0.0% | −0.3—−16.3% | −0.0−121%−9.1% | 0.2r0.1—26.1% | |
| Debt issued | — | — | — | — | 0−100%— | 0.3—2307% | 0—0.0% | — | — | — | |
| Shares issued | — | — | — | 5.4−69.7%— | 18r19+255%— | 5.0+167%41463% | 1.9r1.8−81.5%69.8% | 10−4.5%612% | 11r12+181%2598% | 3.8—563% | |
| Cash from financing activities | 0.3−98.3%— | 15+160%96.7% | 6.0−30.8%— | 8.6−51.0%— | 18r18+252%— | 5.0+27.5%41442% | 3.9−65.3%146% | 11+5.9%684% | 11+205%2619% | 3.5—523% | |
| Exchange-rate effect on cash | 0.2—— | −0.1−259%−0.4% | 0.0—— | −0.1—— | −0.1—— | −0.0−589%−223% | 0.0−30.5%0.2% | 0.0+58.6%0.5% | 0.0−20.7%1.2% | 0.0—0.9% | |
| Change in cash | 4.9+267%— | 1.3—8.3% | −3.6—— | −1.9−128%— | 6.7—— | −2.6—−21486% | −4.2−2233%−157% | 0.2−95.2%12.0% | 4.2—1023% | −4.7r−4.8—−707% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | 1.0—100% | — | — | 0*—— | 0—— | 0−100%— | 0−100%— | 0*—— | 0—— | 0.0—100% | 16—100% | 0*—— | |
| Research and development | 9.1−7.1%— | 1.9−28.6%195% | 2.1−19.8%— | 2.1−16.1%— | 2.9*+52.2%— | 2.7+24.9%— | 2.6+26.4%— | 2.5+50.3%— | 1.9r4.1*+73.1%— | 2.2r1.3—— | 2.0r0.9—10243% | 1.7r1.5—10.5% | 1.1*—— | |
| General and administrative | 6.0+7.5%— | 1.6+9.4%158% | 1.4+2.2%— | 1.6+8.2%— | 1.5*+9.9%— | 1.4+4.5%— | 1.4−12.0%— | 1.5+14.9%— | 1.3*+50.7%— | 1.4—— | 1.5—7690% | 1.3—8.1% | 0.9*—— | |
| Operating expenses | 15+82.1%— | 2.7+239%269% | 2.2−7.6%— | 2.5+7.7%— | 7.3*+185%— | 0.8−77.9%— | 2.4r2.4−6.6%— | 2.3−16.1%— | 2.6*+21.1%— | 3.6—— | 2.6—12824% | 2.8—17.4% | 2.1*—— | |
| Operating income | −14—— | −1.7—−169% | −2.2—— | −2.5—— | −7.3*—— | −0.8—— | −2.4r−2.4—— | −2.3−118%— | −2.6*—— | −3.6—— | −2.5—−12724% | 13—82.6% | −2.1*—— | |
| Interest and finance income | — | — | — | — | — | — | 0.2−34.2%— | 0.3+24.2%— | — | — | 0.3—1711% | 0.2—1.4% | — | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | 0.2—1.4% | — | |
| Other non-operating income (expense) | 0.5−51.2%— | 0.1−40.5%10.6% | 0.1+2.3%— | 0.1−64.6%— | 0.1*−64.6%— | 0.2−5.7%— | 0.1−59.3%— | 0.3+12.7%— | 0.4*—— | 0.2—— | 0.3—1616% | 0.2—1.4% | −0.1*—— | |
| Income before tax | −13—— | −1.6—−158% | −2.1—— | −2.4—— | −7.2*—— | −0.6—— | −2.3—— | −2.1−115%— | −2.2*—— | −3.4—— | −2.2—−11108% | 13—84.1% | — | |
| Income tax | −0.5−134%— | 0.2—16.5% | 0—— | 0−100%— | −0.6*−131%— | −0.6—— | −0.1—— | 0.1—— | 2.1*—— | 0—— | 0—0.0% | 0—0.0% | — | |
| Net income attributable to shareholders | −13—— | −1.7−6627%−175% | −2.1—— | −2.4—— | −6.5*—— | 0.0—— | −2.2—— | −2.2−116%— | −4.2*—— | −3.4—— | −2.2—−11108% | 13—84.1% | −2.3*—— | |
| Earnings per share, basic | — | -0.28−2900%— | -0.34—— | -0.58—— | — | 0.01—— | -0.54—— | -0.52−111%— | — | -0.81—— | -0.53—— | 4.67r0.52—— | — | |
| Earnings per share, diluted | — | -0.28−2900%— | -0.34—— | -0.58—— | — | 0.01—— | -0.54—— | -0.52−115%— | — | -0.81—— | -0.53—— | 3.46r0.38—— | — | |
| Shares, weighted average (basic) | 6.3+46.7%— | 6.3+46.7%— | 6.2+54.9%— | 4.2−1.0%— | — | 4.3+1.8%— | 4.0−4.4%— | 4.2+46.3%— | — | 4.2—— | 4.2—— | 2.9r26—— | — | |
| Shares, weighted average (diluted) | 6.3+44.3%— | 6.3+44.3%— | 6.2+54.9%— | 4.2−1.0%— | — | 4.4+3.5%— | 4.0−4.4%— | 4.2+8.4%— | — | 4.2—— | 4.2—— | 3.9r35—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5.6—24.9% | 5.6+1.1%24.9% | 7.1+588%29.8% | 11+191%51.6% | 8.7+129%35.9% | 5.5−2.3%18.4% | 1.0−84.4%3.2% | 3.8−87.9%11.1% | 3.8+54.5%10.4% | 5.6—14.6% | 6.6—16.1% | 31—73.7% | 2.5—17.9% | |
| Short-term investments | 11—47.9% | 11−22.7%47.9% | 9.8−50.3%41.1% | 2.9−85.7%13.7% | 8.4−63.5%34.6% | 14−40.7%46.4% | 20−7.6%61.5% | 20—59.8% | 23—63.0% | 23—60.8% | 21—52.0% | — | 0—0.0% | |
| Receivables | 0.6—2.8% | 0.6−47.5%2.8% | 1.1−54.9%4.6% | 1.5+15.4%7.3% | 1.5+153%6.3% | 1.2−32.0%4.1% | 2.4+80.3%7.6% | 1.3+604%3.9% | 0.6—1.6% | 1.8—4.6% | 1.3—3.3% | 0.2—0.4% | 0—0.0% | |
| Other current assets | 1.0—4.5% | 1.0+55.1%4.5% | 1.1+17.8%4.7% | 1.2+28.1%5.7% | 1.1−44.1%4.7% | 0.7+38.3%2.2% | 1.0+182%3.0% | 0.9+356%2.8% | 2.0+775%5.6% | 0.5—1.2% | 0.3—0.8% | 0.2—0.5% | 0.2—1.7% | |
| Current assets | 20—89.0% | 20−12.2%89.0% | 21−14.0%89.4% | 19−31.1%88.0% | 22−26.8%89.7% | 23−28.3%76.0% | 25−22.3%77.4% | 27−19.0%79.7% | 30+527%81.4% | 32—82.2% | 32—78.0% | 33—78.9% | 4.7—34.6% | |
| Property, plant and equipment | 0.1—0.4% | 0.1−13.4%0.4% | 0.1−6.7%0.4% | 0.1+1642%0.4% | 0.1+1652%0.4% | 0.1+62.6%0.3% | 0.1+68.3%0.3% | 0.0−61.4%0.0% | 0.0−35.1%0.0% | 0.1—0.2% | 0.1—0.2% | 0.0—0.0% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0.2—1.0% | 0.2−31.0%1.0% | 0.3−25.3%1.1% | 0.3+98.2%1.4% | 0.3+400%1.2% | 0.3+338%1.1% | 0.3+324%1.1% | 0.2+61.3%0.4% | 0.1−46.5%0.2% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | 0.1—0.8% | |
| Other intangible assets | 2.1—9.2% | 2.1−69.1%9.2% | 2.1−69.1%8.7% | 2.1−69.1%9.7% | 2.1−69.1%8.5% | 6.70.0%22.4% | 6.7−24.0%20.9% | 6.7−24.1%19.7% | 6.7−24.1%18.3% | 6.7—17.4% | 8.8—21.6% | 8.8—20.8% | 8.8—64.3% | |
| Total assets | 22—100% | 22−25.1%100% | 24−25.6%100% | 21−37.6%100% | 24−33.5%100% | 30−22.5%100% | 32−21.7%100% | 34−19.8%100% | 36+166%100% | 39—100% | 41—100% | 42—100% | 14—100% | |
| Accounts payable | 0.2—0.9% | 0.2−13.4%0.9% | 0.2−23.4%0.9% | 0.6−36.9%2.8% | 1.1+155%4.4% | 0.2−63.4%0.8% | 0.3+5.2%0.9% | 0.9+192%2.8% | 0.4+101%1.1% | 0.7—1.7% | 0.3—0.7% | 0.3—0.8% | 0.2—1.5% | |
| Current liabilities | 2.5—11.3% | 2.5−2.4%11.3% | 2.4−25.6%10.0% | 2.8−46.9%13.2% | 3.6−39.6%15.0% | 2.6−26.9%8.6% | 3.2+92.4%10.0% | 5.3+231%15.5% | 6.0+268%16.5% | 3.5—9.2% | 1.7—4.1% | 1.6—3.8% | 1.6—11.9% | |
| Lease liabilities (non-current) | 0.1—0.6% | 0.1−49.8%0.6% | 0.2−44.1%0.7% | 0.2+123%0.9% | 0.2+503%0.8% | 0.2+533%0.8% | 0.3+614%0.9% | 0.1+88.3%0.3% | 0.0−43.5%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.1—0.4% | |
| Non-current liabilities | 4.6—20.4% | 4.6−6.4%20.4% | 4.5−31.4%19.1% | 4.5−10.9%21.2% | 4.5−4.7%18.5% | 4.9−1.6%16.3% | 6.6+9.5%20.8% | 5.0−15.1%14.8% | 4.7−21.0%12.9% | 5.0—12.9% | 6.1—14.8% | 5.9—14.0% | 6.0—43.5% | |
| Total liabilities | 7.1—31.6% | 7.1−5.0%31.6% | 6.9−29.5%29.1% | 7.3−29.3%34.4% | 8.1−24.2%33.5% | 7.5−12.1%25.0% | 9.8+27.3%30.7% | 10+36.9%30.3% | 11+41.1%29.4% | 8.5—22.0% | 7.7—18.9% | 7.5—17.8% | 7.6—55.4% | |
| Retained earnings | −160—−717% | −160—−717% | −159—−668% | −157—−738% | −154—−636% | −148—−495% | −148—−462% | −146—−428% | −143—−393% | −139—−361% | −136—−333% | −134—−315% | −147—−1072% | |
| Shareholders' equity | 15—68.4% | 15−31.7%68.4% | 17−23.8%70.9% | 14−41.2%65.6% | 16−37.4%66.5% | 22−25.4%75.0% | 22r22−33.2%69.3% | 24r24−32.1%69.7% | 26+322%70.6% | 30—78.0% | 33—81.1% | 35r35—82.2% | 6.1—44.6% | |
| Total liabilities and equity | 22—100% | 22−25.1%100% | 24−25.6%100% | 21−37.6%100% | 24−33.5%100% | 30−22.5%100% | 32−21.7%100% | 34−19.8%100% | 36+166%100% | 39—100% | 41—100% | 42—100% | 14—100% | |
| Shares outstanding | 4.4—— | 4.4+28.9%— | 4.4+28.9%— | 4.0+33.1%— | 3.8+25.4%— | 3.4+14.4%— | 3.4+15.6%— | 3.0−88.6%— | 3.0+250%— | 3.0—— | 3.0—— | 26—— | 0.9r7.7—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0+118%— | 0.0*+15.1%1.2% | 0.0*+214%— | 0.0+3222%— | 0.0*+77.7%— | 0.0*+404%— | 0.0*−45.9%— | 0.0−93.5%— | 0.0*−25.5%— | 0.0*—— | 0.0*—31.6% | 0.0—0.0% | 0.0*—— | |
| Share-based compensation | 0.7−10.5%— | 0.2*−26.8%18.6% | 0.1*−58.4%— | 0.2+41.0%— | 0.2*+46.4%— | 0.3*+48.6%— | 0.3*+75.4%— | 0.1−15.3%— | 0.2*−12.2%— | 0.2*—— | 0.1*—749% | 0.2—1.1% | 0.2*—— | |
| Cash from operating activities | −7.8—— | −0.6*—−55.8% | −1.9*—— | −3.2—— | −2.2*—— | −1.3*−238%— | −3.8*—— | −2.7−120%— | −2.3*—— | 0.9*—— | −3.7*—−18667% | 14—85.2% | −2.6*—— | |
| Capital expenditure | −0.1—— | −0.0*—−0.0% | −0.0*—— | −0.0—— | −0.1*—— | −0.0*—— | −0.0*—— | 0—— | — | 0*—— | — | — | 0*—— | |
| Cash from investing activities | 2.9−69.6%— | −1.0*−117%−95.8% | −6.9*−1137%— | 5.4+102%— | 5.3*+1008%— | 5.7*—— | 0.7*—— | 2.7—— | 0.5*—— | −1.9*—— | −21*—−106125% | 0—0.0% | 0*—— | |
| Shares issued | — | — | — | — | — | — | — | — | — | 0*—— | 0*—0.0% | 0—0.0% | — | |
| Cash from financing activities | 4.9+1751%— | −0.0*—−0.7% | 4.9*+1754%— | −0.0—— | 0.0*—— | 0*—— | 0.3*+5.9%— | 0−100%— | 0*—— | 0*—— | 0.3*—1253% | 15—95.3% | −0.5*—— | |
| Exchange-rate effect on cash | 0.0−50.0%— | 0.0*+32.4%1.7% | −0.0*−113%— | 0.0+98.2%— | 0.0*—— | 0.0*−78.9%— | 0.1*+1785%— | 0.0—— | −0.1*−162%— | 0.1*—— | 0.0*—34.9% | −0.1—−0.3% | 0.1*—— | |
| Change in cash | 0.1—— | −1.5*−134%−151% | −3.9*—— | 2.3—— | 3.2*—— | 4.5*—— | −2.7*—— | −0.0−100%— | −1.8*—— | −0.9*—— | −25*—−123504% | 29—180% | −2.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Kiora Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2024#
As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- Reportable$16 M100%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2024
Executive pay at Kiora Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Dr. Strem | $972 K | $949 K | $737 K | — |
| 2024Brian M. Strem | $955 K | $949 K | $604 K | — |
| 2023Brian M. Strem | $805 K | $710 K | $530 K | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Kiora Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2026 | $5 M | Private placement after listing | $2 to $10 million | 3 | equity, options | SEC |
| Feb 2024 | $15 M | Private placement after listing | $10 to $50 million | 13 | equity, options | SEC |
| Aug 2021 | $11 M | Private placement after listing | $10 to $50 million | 14 | options | SEC |
| Jan 2021 | $8 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Dec 2020 | $3 M | Private placement after listing | $2 to $10 million | 15 | equity | SEC |
| Oct 2019 | $2 M | Private placement after listing | Under $2 million | 1 | equity, options | SEC |
| Jun 2016 | $4 M | No. 3 | $2 to $10 million | 2 | options | SEC |
| Mar 2016 | $3 M | Issued in a merger or acquisition | $2 to $10 million | 32 | equity | SEC |
| Dec 2010 | $4 M | No. 2 | $2 to $10 million | 9 | equity | SEC |
| Dec 2009 | $11 M | No. 1 | $10 to $50 million | 20 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Kiora Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$8 M · higher than 8% of 726
- Price / book0.5× · lower than 92% of 534
- FCF yield-129.3% · higher than 6% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Kiora Pharmaceuticals, Inc.🇺🇸 | $8 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Kiora Pharmaceuticals, Inc.? Verify and update this profile — free
Show Kiora Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.